%0 Journal Article
%A Pei, Yanxin
%A Liu, Kun-Wei
%A Wang, Jun
%A Garancher, Alexandra
%A Tao, Ran
%A Esparza, Lourdes A
%A Maier, Donna L
%A Udaka, Yoko T
%A Murad, Najiba
%A Morrissy, Sorana
%A Seker-Cin, Huriye
%A Brabetz, Sebastian
%A Qi, Lin
%A Kogiso, Mari
%A Schubert, Simone
%A Olson, James M
%A Cho, Yoon-Jae
%A Li, Xiao-Nan
%A Crawford, John R
%A Levy, Michael L
%A Kool, Marcel
%A Pfister, Stefan
%A Taylor, Michael D
%A Wechsler-Reya, Robert J
%T HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
%J Cancer cell
%V 29
%N 3
%@ 1535-6108
%C Cambridge, Mass.
%I Cell Press
%M DKFZ-2017-05383
%P 311 - 323
%D 2016
%X Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.
%K Forkhead Transcription Factors (NLM Chemicals)
%K Histone Deacetylase Inhibitors (NLM Chemicals)
%K Proto-Oncogene Proteins c-myc (NLM Chemicals)
%K Phosphatidylinositol 3-Kinases (NLM Chemicals)
%K Histone Deacetylases (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:26977882
%2 pmc:PMC4794752
%R 10.1016/j.ccell.2016.02.011
%U https://inrepo02.dkfz.de/record/130304